Alzheimer's disease biomarker states

The Lancet Neurology

Volumn 15, Issue 1, 2016, Pages 25-26

  Vos, Stephanie J B ^a   Fagan, Anne M ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ALZHEIMER DISEASE; AMYLOIDOSIS; CLINICAL EXAMINATION; CLINICAL PRACTICE; COGNITIVE DEFECT; CROSS-SECTIONAL STUDY; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NEUROIMAGING; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; DEMENTIA; DISEASE COURSE; FEMALE; HEALTH SURVEY; MALE; NEURODEGENERATIVE DISEASES; PLAQUE, AMYLOID;

DEMENTIA; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; NEURODEGENERATIVE DISEASES; PLAQUE, AMYLOID; POPULATION SURVEILLANCE;

EID: 84947339771     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(15)00335-X     Document Type: Note

References (11)

1. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:280-292.
2. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:270-279.
3. Knopman DS, Jack CR, Wiste HJ, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012, 78:1576-1582.
4. Vos SJ, Verhey F, Frolich L, et al. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain 2015, 138:1327-1338.
5. Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol 2013, 12:957-965.
6. Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 2015, 313:1924-1938.
7. Jack CR, Wiste HJ, Weigand SD, et al. Age, sex, and APOE epsilon 4 effects on memory, brain structure, and beta-amyloid across the adult life span. JAMA Neurol 2015, 72:511-519.
8. Jack CR, Wiste HJ, Weigand SD, et al. Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. Lancet Neurol 2014, 13:997-1005.
9. Jack CR, Therneau TM, Wiste HJ, et al. Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. Lancet Neurol 2015, published online Nov 17. http://dx.doi.org/10.1016/S1474-4422(15)00323-3.
10. Jack CR, Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 2012, 71:765-775.
11. Jack CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013, 12:207-216.